- Display 45 Products per page
Published: June 1, 2010 | Price: $3,995.00 – $7,990.00
Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 22 suppliers, representative of those active in this market. Segments covered in this report include: Chemistry Services Building Blocks Compound Synthesis Libraries Process Research Other Services Biology Services Protein...Published: May 11, 2012 | Price: $3,995.00 – $7,990.00
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery...Published: March 20, 2018 | Price: $4,500.00 – $9,000.00
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition In eight editions, Kalorama Information's report, Outsourcing in Drug Discovery, has kept the industry informed, providing answers to these questions and more. The 8th edition contains 2017 market size estimates and 2022 forecasts for 21 different parts of the process that might be outsourced, including: Chemistry Services Market, 2017-2022 Building Blocks Outsourcing Market, 2017-2022 Compound Synthesis Market, 2017-2022 Library Construction Market, 2017-2022 Process Research Market, 2017-2022 Biology Services...Published: April 30, 2014 | Price: $995.00 – $1,990.00
For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. This Kalorama Information Report, Outsourcing in Drug Discovery, t provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. As part of its coverage, the report provides markets and forecasts for the following segments. Chemistry Services Market: Building Blocks, Compound Synthesis, Libraries,...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...Published: May 30, 2018 | Price: $11,995.00 – $23,990.00
Kalorama Information Market Research Bundles allow customers to experience savings while obtaining a large amount of research on topics of importance in pharmaceuticals. This bundle represents essential trends in the pharmaceutical industry currently. It is combination of 4 complete Kalorama Information reports, including the following: What's Trending in Monoclonal Antibodies Biopharmaceutical Contract Manufacturing Organization Markets Single-Use Upstream Bioprocessing Markets The World Market for BiosimilarsThe reports are separate PDFs, exactly as they were published, combined into one. A separate Table of...Published: July 1, 2008 | Price: $500.00 – $7,000.00
Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...Published: April 1, 2009 | Price: $995.00 – $2,590.00
The pharmaceutical market in India ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be essential for pharmaceutical companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This report Pharmaceutical Market in India provides market watchers with needed information on this growing market, including: Market Size and Forecast...Published: January 1, 2009 | Price: $995.00 – $1,990.00
The pharmaceutical market in Russia ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be one of several that major pharmaceutical companies are exploring for new opportunities for growth. Reliance on commodity prices makes Russia's economy and government spending on healthcare variable, but awareness of healthcare issues, especially among the younger population, and a willingness to spend personal funds on healthcare will drive Russian markets. For the...Published: November 1, 2008 | Price: $995.00 – $1,990.00
At present the Middle East region constitutes as small percent of global pharmaceutical sales. However, ever-increasing populations and governmental healthcare reforms are likely to increase demand. These markets will be essential for pharmaceuticals companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This Kalorama Information report, Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends) takes a thorough look at the...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: September 1, 2006 | Price: $3,900.00 – $7,800.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...Published: January 1, 2009 | Price: $995.00 – $7,000.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...Published: August 3, 2012 | Price: $2,500.00 – $5,000.00
What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the...Published: July 1, 2010 | Price: $995.00 – $1,990.00
What Will The Pharmaceutical Market Look Like in the Next Five Years?In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a...Published: May 15, 2017 | Price: $3,360.00 – $6,720.00
Potential Pipeline Disruptors: Innovative Pharmaceuticals in Alzheimer's Disease, Asthma and Cancer This report covers market opportunities based on pipeline developments for six key therapeutic specialities: Alzheimer's Disease Asthma Breast Cancer Leukemia Lung Cancer Lymphoma These six areas are expected to show the strongest pipeline impact and candidates are likely to replace current therapies. The market is evaluated for 2015 and 2016 with forecast data provided through 2022. Forecast data were derived from a combination of pipeline analyses, current product treatment...Published: October 25, 2022 | Price: $5,000.00 – $10,000.00
Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...Published: September 1, 2006 | Price: $1,500.00 – $7,000.00
This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture...Published: January 1, 2007 | Price: $995.00 – $7,000.00
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: March 1, 2008 | Price: $995.00 – $3,990.00
Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including. Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...Published: November 1, 2003 | Price: $2,246.00 – $4,492.00
Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet...Published: May 1, 2009 | Price: $995.00 – $7,000.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's...Published: April 1, 2005 | Price: $995.00 – $1,990.00
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...Published: April 1, 2007 | Price: $1,295.00 – $2,995.00
SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban currently holds a tenuous lock on, is about to change, with a major new brand ready to shake up the current market share. At the...Published: November 1, 2008 | Price: $995.00 – $3,000.00
Smoking cessation is among the most dynamic pharmaceutical markets, and one that is expected to grow despite economic conditions. More than 5 million deaths are attributed to nicotine each year. This has encouraged public health entities to pursue smoking cessation, and has driven development of smoking cessation products, both prescription and over the counter. The arrival of Chantix/Champix and its unique marketing strategy and a robust pipeline bodes well for growth in this pharmaceutical segment. This report, Smoking Cessation: World...Published: April 16, 2019 | Price: $5,000.00 – $10,000.00
Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. The 2019 Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress. This report covers targeted cancer therapies that do at least one of the following: Block or turn off chemical signals that tell the cancer...Published: November 1, 2006 | Price: $1,200.00 – $7,000.00
Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. Each market segment provides an overview, descriptions of products available...Published: April 1, 2006 | Price: $3,500.00 – $7,000.00
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: August 1, 2005 | Price: $2,500.00 – $5,000.00
This market briefing concentrates on the U.S. market for medical nutritional support—in particular, the enteral and parenteral foods. The continuing development of equipment, medical foods, and feeding procedures that secure the nutrition of critically ill patents has greatly improved recovery and survival in select populations. Advances in the effectiveness and safety of nutritional procedures and techniques have evolved from steady improvements, including the use of antibiotic materials, biosensors, wireless communications, and more efficient pumps and controllers. These new developments have...Published: November 1, 2003 | Price: $1,875.00 – $3,750.00
The process of creating a new drug is lengthy and complex. From discovery to development to market, there are numerous pitfalls. In this report, Kalorama focuses on one of the trickiest yet also most promising areas: the interface between discovery and development known as lead optimization. The pressure is on: get better lead compounds faster and at less cost. The amount of money wasted on leads that fail is excessive. And the attrition rate to get a lead is huge....Published: July 14, 2016 | Price: $2,800.00 – $5,600.00
The Market for Needle-Free Drug Delivery Systems The Market for Needle-Free Drug Delivery Systems, details the revenue opportunity for needle-free drug systems. The report contains seven important conclusions about the market. It also provides market estimate and forecast for jet technology and market estimate and forecast for other needle-free technology, as well as estimates and forecasts of the insulin, vaccine, pediatric, and pain needle-free delivery market segments. Becton Dickinson, Antares Pharma, Inc., Akra D ermojet, and 3M Pharmaceuticals are among...Published: February 1, 2011 | Price: $150.00 – $300.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over-the-counter status where possible. In the early part of the last decade there was a decline in Rx-to-OTC switches; since 2006, however, there has been a number of uses of this tactic to extend the revenue of pharmaceutical products. In Kalorama Information's Market for...Published: May 5, 2022 | Price: $6,000.00 – $12,000.00
More than 700 pharmaceutical products have made the switch from Rx to OTC over the past several decades. The U.S. Rx-to-OTC market has grown into a $13.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness to work with industry, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective...Published: December 4, 2012 | Price: $500.00 – $1,000.00
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar...Published: July 1, 2005 | Price: $3,000.00 – $6,000.00
This report on the U.S. market for over-the-counter (OTC) cough, cold, sinus and allergy (CCSA) medication presents an in-depth analysis of the performance of various CCSA drugs in the U.S. market. The analysis captures the performance of the market players, drug categories, and leading brands in terms of revenues and growth. It also identifies key issues, drivers, challenges, regulations, and trends affecting the marketplace. In addition, the report provides a detailed analysis of consumer demographics and preferences in terms of...Published: January 1, 2006 | Price: $3,000.00 – $6,000.00
The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive report examines all aspects of the U.S. OTC market, including 5-year sales performance by brand and by marketer for the following categories of products: Antifungals...Published: January 1, 2005 | Price: $3,000.00 – $6,000.00
The U.S. market for Over-the-Counter (OTC) Pain Medication presents an in-depth analysis of the performance of various analgesics, including non-steroidal anti-inflammatory drugs (NSAID) and topical products in the US market. The analysis captures the performance of the market players, categories and leading brands in terms of revenue growth and volume growth. It also identifies key issues, drivers, challenges, regulations and trends affecting the marketplace. The report provides a comprehensive analysis of the pain medication products that are currently in the...Published: February 1, 2006 | Price: $3,000.00 – $6,000.00
The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade. This report on the U.S. market for OTC private label products presents an in-depth analysis of the...Published: January 11, 2013 | Price: $3,995.00 – $7,990.00
The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription. This report represents the six time that Kalorama Information has analyzed the market for drugs with switched ingredients in detail. The market is fueled by several factors including an aging population; steady to increased incidences of conditions and diseases; new drug classes switched to OTC; product demand; economic conditions and several other...Published: February 2, 2015 | Price: $1,995.00 – $3,995.00
The US Market for Rx to OTC Switches Prescription products that are marketed as consumer products are known as Rx-to-OTC. They represent an important part of pharmaceutical strategy and a growing market. This report, The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. Patient-consumer awareness of health issues is driving the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the...